Significant Burden of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Iranian Population: A Cross-Sectional Analysis

  • Behnam Hosseini Ahangar Baqiyatalah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Rojen Manheouchri School of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
  • Bahareh Rezaei School of Medicine, Kashan University of Medical Sciences and Health Services, Kashan, Iran.
  • Maryam Bahadori School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Arefeh Ebrahimi School of Medicine, University Medicine Greifswald, Greifswald, Germany
  • Rilind Krasniq Department of Cardiology, Angiology and Sleep Medicine, Bonifatius Hospital Lingen, Lingen, Germany .
  • Ehsan Shahverdi Department of Cardiology, Angiology and Sleep Medicine, Bonifatius Hospital Lingen, Lingen, Germany
Keywords:
Non-alcoholic fatty liver disease (NAFLD), Fatty liver, Fibrosis, Chronic liver disease

Abstract

The main cause of chronic liver disease in Iran is Non-alcoholic fatty liver disease (NAFLD). A common pathological feature of chronic liver disease is fibrosis, so particular vigilance against patients with liver fibrosis is necessary to lead healthcare resource planning. The aims of the current study were to determine the prevalence and predictors of significant fibrosis and advanced ones among individuals with NAFLD. In the current cross-sectional study conducted during 2013-2016, the presence of fibrosis among NAFLD patients was assessed using the NAFLD fibrosis score (NFS) and AST to Platelet Ratio Index (APRI) systems. Multivariate logistic regression models were used to predict significant fibrosis or advanced fibrosis among NAFLD patients. Analysis of the results of over 999 patients (569 females and 430 males) with the mean age of 43.28±14.034 years in Iran during 2015-2016 showed that the overall prevalence of NAFLD among Iranian adults was 19.6%. NAFLD prevalence was not significantly higher in males compared to females (51.5% vs. 48.5%, P=0.66). On multivariate logistic regression analyses, females were less likely to have NAFLD compared to males (OR 0.32, 95% CI 0.24-0.42, P<0.001). The overall prevalence of liver fibrosis among NAFLD patients was 38.8%.20.4% and 6.12% of NAFLD patients had evidence of significant and advanced fibrosis, respectively. Our most recent dataset analysis emphasized the major burden of  NAFLD among people of Iranian origin. A high prevalence of individuals with NAFLD and advanced fibrosis was observed.

Published
2020-05-13
How to Cite
1.
Hosseini Ahangar B, Manheouchri R, Rezaei B, Bahadori M, Ebrahimi A, Krasniq R, Shahverdi E. Significant Burden of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Iranian Population: A Cross-Sectional Analysis. Acta Med Iran. 57(11):653-657.
Section
Articles